323 related articles for article (PubMed ID: 28361290)
21. Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.
Akanmu AS; Adeyemo T; Lesi F; Bello FO; Okwuegbuna K; Oloko K; Awolola A; Ogunsola FT; Okonkwo P; Kanki PJ
Curr HIV Res; 2015; 13(3):176-83. PubMed ID: 25986368
[TBL] [Abstract][Full Text] [Related]
22. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
Gianotti N; Cozzi-Lepri A; Antinori A; Castagna A; De Luca A; Celesia BM; Galli M; Mussini C; Pinnetti C; Spagnuolo V; d'Arminio Monforte A; Ceccherini-Silberstein F; Andreoni M;
PLoS One; 2017; 12(2):e0171611. PubMed ID: 28192453
[TBL] [Abstract][Full Text] [Related]
23. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
24. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
25. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
Arathoon E; Schneider S; Baraldi E; Lim PL; Opravil M; Van De Casteele T; Lavreys L
Int J STD AIDS; 2013 Jan; 24(1):12-7. PubMed ID: 23440570
[TBL] [Abstract][Full Text] [Related]
26. Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
Andersson LM; Vesterbacka J; Blaxhult A; Flamholc L; Nilsson S; Ormaasen V; Sönnerborg A; Gisslén M
Scand J Infect Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23294034
[TBL] [Abstract][Full Text] [Related]
27. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
Brogan AJ; Davis AE; Goodwin B
PLoS One; 2018; 13(8):e0203293. PubMed ID: 30161205
[TBL] [Abstract][Full Text] [Related]
28. Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study).
Gianotti N; Galli L; Maserati R; Sighinolfi L; Ripamonti D; Palvarini L; Lo Caputo S; Focà E; Celesia BM; Baldelli F; Sterrantino G; Lazzarin A
New Microbiol; 2016 Oct; 39(4):290-294. PubMed ID: 27551725
[TBL] [Abstract][Full Text] [Related]
29. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
30. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
31. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
Lombardi F; Belmonti S; Quiros-Roldan E; Latini A; Castagna A; D'Ettorre G; Gagliardini R; Fabbiani M; Cauda R; De Luca A; Di Giambenedetto S;
J Antimicrob Chemother; 2017 Jul; 72(7):2055-2059. PubMed ID: 28333353
[TBL] [Abstract][Full Text] [Related]
32. An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Laker EAO; Nabaggala MS; Kaimal A; Nalwanga D; Castelnuovo B; Musubire A; Kiragga A; Lamorde M; Ratanshi RP
BMC Infect Dis; 2019 Mar; 19(1):280. PubMed ID: 30909871
[TBL] [Abstract][Full Text] [Related]
33. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
34. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
[TBL] [Abstract][Full Text] [Related]
35. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.
Baril J; Conway B; Giguère P; Ferko N; Hollmann S; Angel JB
HIV Med; 2014 May; 15(5):301-10. PubMed ID: 24314017
[TBL] [Abstract][Full Text] [Related]
37. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
38. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Rockwood N; Mandalia S; Bower M; Gazzard B; Nelson M
AIDS; 2011 Aug; 25(13):1671-3. PubMed ID: 21716074
[TBL] [Abstract][Full Text] [Related]
39. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
Hill A; Marcelin AG; Calvez V
HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]